Myasthenia Gravis (MG)

Myasthenia gravis is an autoimmune disease where the immune system attacks the body’s own tissues, interrupting the connection between nerves and muscles.

Featured Article

The Expanding Therapeutic Landscape for Myasthenia Gravis

By MDA Staff | August 14, 2020
Blog Post

Momenta Pharmaceuticals Announces Positive Results from Phase 2 Vivacity-MG Study of Nipocalimab for Treatment of Generalized Myasthenia Gravis

By Sujatha Gurunathan | June 18, 2020
Featured Article

MDA’s 2020 Clinical Scientific Conference Trial News and Updates

By MDA Staff | May 15, 2020
Blog Post

Clinical Trial Alert: Momenta Pharmaceuticals Seeks Participants for a Phase 2 Myasthenia Gravis Study

By MDA Staff | October 15, 2019
Blog Post

Simply Stated: What is Myasthenia Gravis?

By Jeanene Swanson | July 2, 2019
Blog Post

Clinical Trial Alert: Alexion Pharmaceuticals Seeks Participants for a Phase 3 Pediatric Myasthenia Gravis Study

By MDA Staff | May 30, 2019
A pyramid of tan building blocks with red medical insignia on it
Featured Article

Prepare Yourself

By Donna Albrecht | March 26, 2019
Blog Post

Long-Term Results of Extension Study Validate Surgery as a Treatment for Myasthenia Gravis

By Jeanene Swanson | February 12, 2019
MDA logo
Blog Post

Catalyst Pharmaceuticals Announces Positive Results from Phase 2b Trial of Firdapse in Patients with Muscle-Specific Kinase Antibody Positive Myasthenia Gravis (MuSK-MG)

By Jeanene Swanson | January 30, 2019